CR-845 Emerging Drug Insight and Market Forecast - 2032

“CR-845 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about CR-845 for Postoperative Pain in the 7MM. A detailed picture of the CR-845 for Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the CR-845 for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CR-845 market forecast, analysis for Postoperative Pain in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Postoperative Pain.

Drug Summary

Cara Therapeutics is developing the first peripherally acting kappa opioid receptor agonist (KORA) called CR845. The drug is a potent peripheral kappa-opioid receptor agonist with high selectivity over other opioid receptors in the body. The degree of kappa receptor selectivity displayed by CR-845 is best-in-class compared to all other previously developed compounds for this therapeutic target.

The drug is designed to produce pain relief by specifically stimulating kappa, rather than mu, opioid receptors. Moreover, the drug is designed with specific chemical characteristics to restrict its entry into the CNS and further limit the mechanism of action to kappa opioid receptors in the peripheral nervous system, consisting of the nerves outside the brain and spinal cord.

CR845 also exhibits potent analgesic, antipruritic and anti-inflammatory properties. Since the drug is intrinsically poor at penetrating the blood-brain barrier, it has shown to produce little to no CNS-mediated side effects that one sees with traditional CNS-acting mu opioids like nausea/vomiting, sedation, respiratory depression, abuse, addiction or euphoria. CR845 has been formulated both as an intravenous and an oral formulation, and it has been studied for both pain and pruritus (itch). The company is currently assessing the best path forward for IV CR845/difelikefalin in the postoperative acute care setting.

Cara Therapeutics holds worldwide commercialization rights other than South Korea and Japan, where CKPD and Maruishi hold the commercialization rights for CR845 (IV) in acute postoperative pain/PONV.

Cara Therapeutics has completed an advisory meeting with the FDA regarding the potential regulatory path forward for PONV, and they are currently evaluating potential next steps.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CR-845 description, mechanism of action, dosage and administration, research and development activities in Postoperative Pain.
• Elaborated details on CR-845 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CR-845 research and development activity in Postoperative Pain details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CR-845.
• The report contains forecasted sales of CR-845 for Postoperative Pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative Pain.
• The report also features the SWOT analysis with analyst views for CR-845 in Postoperative Pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CR-845 Analytical Perspective

In-depth CR-845 Market Assessment

This report provides a detailed market assessment of CR-845 in Postoperative Pain in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

CR-845 Clinical Assessment

The report provides the clinical trials information of CR-845 for Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Postoperative Pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CR-845 dominance.
• Other emerging products for Postoperative Pain are expected to give tough market competition to CR-845 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CR-845 in Postoperative Pain.
• Our in-depth analysis of the forecasted sales data of CR-845 from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CR-845 in Postoperative Pain.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of CR-845?
• What is the clinical trial status of the study related to CR-845 in Postoperative Pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CR-845 development?
• What are the key designations that have been granted to CR-845 for Postoperative Pain?
• What is the forecasted market scenario of CR-845 for Postoperative Pain?
• What are the forecasted sales of CR-845 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Postoperative Pain and how are they giving competition to CR-845 for Postoperative Pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative Pain?